IRCT20220111053692N18已完成Unknown
Bioequivalence study of Empagliflozin ?? mg (Tehran Chemie Pharmaceutical Company) versus Jardiance(Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers
Tehran Chemie Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- Male
入选标准
- •18 to 55 years old.
- •Weight in range of 10 % proper body weight.
- •All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test.
- •Possessing negative test for hepatitis B surface antigen (HBs-Ag), Antihepatitis-C antibody (anti-HCV) and anti-HIV.
- •just the man
排除标准
- •Volunteers with hypersensitivity to Empagliflozin were excluded.
- •Those with known history of drug abuse. alcohol consumer or cigarette smokers.
- •Taking medications that have drug interactions with Empagliflozin until one month before studying.
- •Disinclination to take the test.
- •Blood donation or blood loss of more than 200 ml in the past month.
研究者
相似试验
招募中
Unknown
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
招募中
不适用
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24
招募中
Unknown
Bioequivalence study of Empagliflozin 25 mg tabletIRCT20200105046010N83kharazmi company24